AR882 75 mg

DRUG3 trials

Sponsors

Arthrosi Therapeutics

Conditions

Arthritis, GoutyGoutGout ChronicGouty ArthritisHyperuricemiaRefractory GoutTophaceous GoutUncontrolled Gout

Phase 2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

Active, not recruitingNCT07116746

Arthrosi TherapeuticsGout, Gout Chronic, Gouty Arthritis +4

Start: 2025-12-03End: 2027-02-01Target: 15Updated: 2026-05-15

Phase 3

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

CompletedNCT06439602

Arthrosi TherapeuticsArthritis, Gouty, Gout, Gout Chronic +1

Start: 2024-06-26End: 2026-04-10Updated: 2026-08-31

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Active, not recruitingNCT06846515

Arthrosi TherapeuticsArthritis, Gouty, Gout, Gout Chronic +1

Start: 2025-03-11End: 2026-10-01Target: 750Updated: 2026-08-31